Cosmetic composition containing retinoid, centella asiatica extract and dipeptide
By combining encapsulated retinoids, Centella asiatica extract and dipeptides in cosmetics, the side effects of high-content retinol are solved, achieving efficient anti-aging and skin soothing effects, suitable for reducing signs of aging and enhancing the skin healthy.
Patent Information
- Application Number
- CN202380033262.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-18
- Filing Date
- 2023-02-16
- Publication Date
- 2024-12-03
AI Technical Summary
High content of retinol or retinaldehyde in existing cosmetics can cause skin side effects, such as irritation, redness, peeling and dry skin, and increase sensitivity to sunlight, making it difficult to effectively reduce these side effects. At the same time, local administration of vitamin A derivatives requires conversion, Limit its wide application.
Using cosmetic compositions including retinoids, Centella asia extract and dipeptides, retinoids are encapsulated to protect their stability, and to reduce skin sensitivity by using the anti-inflammatory and antioxidant effects of Centella asia, Combined with the skin soothing effect of dipeptides, it forms a highly effective anti-aging cosmetic.
While reducing skin side effects, it improves the anti-aging effect of cosmetics and enhances the skin's renewal and regeneration ability, especially in the skin areas exposed to the sun, which significantly reduces signs of aging.
Smart Images

Figure BDA0005076821570000091 
Figure BDA0005076821570000191 
Figure BDA0005076821570000231
Abstract
Description
Technical Field
[0001] The present invention relates to cosmetic compositions and methods of using such cosmetic compositions. More particularly, the present invention relates to cosmetic compositions comprising retinoids designed to provide anti-aging skin benefits to the user. Background Art
[0002] The applicant has been working for many years on the study of the skin aging process and developing skin care compositions to combat the natural effects of aging on the skin. The applicant is well known for its collaborations with renowned universities in the field of peptides and their effects on the skin, as well as its collaborations with peptide suppliers to produce peptides of interest. However, more recently, the applicant has focused on understanding other mechanisms that influence and improve the appearance of the skin, and in particular the benefits of vitamin A and its derivatives.
[0003] It is well known in the art of cosmetic composition design and manufacture that the skin can be negatively affected by endogenous and exogenous factors. Endogenous factors include hormonal fluctuations, inflammation, disease and / or the normal aging process. Exogenous factors that affect the skin include environmental influences, such as sunlight, wind erosion, humidity and pollutants. The effects of these factors on the skin lead to problems associated with skin aging, such as the formation of wrinkles, fine lines, age spots, enlarged pores, skin discoloration, surface roughness and loss of elasticity.
[0004] There are a variety of over-the-counter and prescription drugs that can be used to treat signs of aging and / or promote skin health. However, people have recently become interested in using vitamin A derivative products in this context. Vitamin A and its derivatives are naturally present in the human body and skin, and they need to be converted to retinoic acid by cells to work. Therefore, topical application of retinoic acid is highly effective because it does not require any conversion, but it has potential side effects on the skin and is therefore only available by prescription. Therefore, since a large proportion of consumers cannot obtain products containing retinoic acid, cosmetic manufacturers have turned their attention to retinyl esters in over-the-counter products, and in particular retinol, to treat signs of aging and improve skin quality or appearance. Retinol is the most effective cosmetic substitute for retinoic acid. It binds to surface cell receptors before entering skin cells and is then converted to retinoic acid, which upregulates more than 500 genes related to skin renewal, regeneration and homeostasis via nuclear receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs). This is particularly beneficial for skin parts exposed to the sun, such as the face, thereby reducing signs of aging such as dull skin and reduction of pigmentation.
[0005] However, high levels of retinol or retinal in products can also lead to adverse skin side effects, including but not limited to irritation, redness, stinging, itching, scaling, peeling and dry skin, or more serious side effects, including but not limited to severe burning, blistering, crusting or swelling of the skin, changes in skin pigmentation, or worsening of eczema. In addition, if the top layer of skin peels, it may become more sensitive to sunlight and sun-induced damage. Finally, if the skin is irritated, it may be further aggravated by environmental changes and the use of other cosmetics (such as soaps or cleansers).
[0006] It is therefore an object of the present invention to provide a first cosmetic composition for topical application to the skin comprising a highly potent level of an anti-aging retinoid while also reducing the potential harmful side effects noted above. Summary of the invention
[0007] According to the present invention, there is provided a cosmetic composition comprising a retinoid, a Centella asiatica extract and a dipeptide. DETAILED DESCRIPTION
[0008] Unless otherwise stated, references to compositions herein are references to compositions of all aspects of the invention.
[0009] Retinoids
[0010] The present invention includes retinoids. The retinoid is preferably selected from the group consisting of retinol, retinol isomers, retinal (also known as retinal), retinal isomers, and mixtures thereof.
[0011] The term "retinol isomers" includes the following: all-trans retinol, 13-cis retinol, 11-cis retinol, 9-cis retinol, 3,4-didehydroretinol. Preferred isomers are all-trans retinol, 13-cis retinol, 3,4-didehydroretinol, 9-cis retinol. In one embodiment of the present invention, the retinoid is selected from the group consisting of all-trans retinol.
[0012] The term "retinal isomers" includes the following: 11-cis-retinal and all-trans-retinal. In one embodiment of the present invention, the retinoid is selected from the group consisting of all-trans-retinal.
[0013] When exposed to light, temperature changes and oxygen, retinoids become unstable and degrade into less biologically active forms, and therefore, in one embodiment, the retinoid component is preferably encapsulated. Encapsulation is designed to protect the retinoid material to prevent or at least reduce degradation, thereby maximizing the bioavailability of the retinoid to the skin during use. Various mechanisms and materials for encapsulating retinoids have been described in the prior art. Examples of encapsulation materials include polymers, surfactant-based vesicles or liposomes. Preferred polymeric encapsulation materials include polysaccharides. In one embodiment, the retinoid is encapsulated in a polysaccharide preparation including chitosan. In one embodiment, the retinoid is encapsulated in a polysaccharide preparation including inulin. In one embodiment, the retinoid is encapsulated in a polysaccharide preparation including hydroxypropyl cyclodextrin.
[0014] In one embodiment, the retinoid can be encapsulated with a material selected from the group consisting of: a sugar-based emulsifier, a co-emulsifier, a positively charged molecule, a solvent, and a mixture thereof. An example of a preferred retinoid raw material component can be commercially available under the trade name InuMax sold by Evonik. Other commercially available encapsulated forms of retinol include Cyclasphere retinol from BASF, Microsponge C116A, N720RE and N709RE from Amcol Health & Beauty Solutions, and Spherulite-R10 from Givaudan. Other non-encapsulated forms of stabilized retinol are also available, such as RetiSTAR stabilized retinol from BASF.
[0015] The level of retinoid present in the composition of the present invention is at least 0.5% by weight of the composition. In one embodiment, the level of retinoid present in the composition of the present invention is at least 0.75% by weight of the composition. In another alternative embodiment, the level of retinoid component present in the composition of the present invention is at least 1% by weight of the composition.
[0016] When referring to the level of retinoid in the composition, it is expressed as the level of active retinoid by weight in the composition and not the weight percentage of the retinoid-containing raw material as provided by the supplier.
[0017] Centella asiatica
[0018] The compositions of the present invention include Centella asiatica, also known as Gotu kola or India Pennyworth. The inventors were surprised to find that, in the presence of high concentrations of retinoids in the composition, Centella asiatica is more effective than other known skin soothing agents, such as, for example, bisabolol, in reducing skin sensitivity. While not wishing to be bound by theory, it is believed that the success achieved with Centella asiatica is due to its ability to target transcription factors such as NF-Kb that are used to regulate downstream inflammatory cascades. For example, inhibition of NF-Kb will in turn lead to reduced production of many different inflammatory mediators such as TNF-α, IL-1β, IL-6, and prostaglandin E. Therefore, Centella asiatica can promote skin soothing by affecting a wider range of pro-inflammatory biological pathways. In contrast, bisabolol has been shown to more selectively affect pro-inflammatory cytokine targets by binding to cytokine active sites.
[0019] In one embodiment, Centella asiatica is preferably extracted from the leaves of the plant. In one embodiment, Centella asiatica is characterized by the presence of bioactive triterpenes, including madecassoside, which contribute to the biological efficacy of the extract. In one embodiment, Centella asiatica is characterized by the presence of a polyphenolic fraction, which contributes to the biological efficacy of the extract. Centella asiatica provides antioxidant benefits and promotes the synthesis of type I and type III collagen. An extract of Centella asiatica is commercially available from Indena under the trade name Centevita.
[0020] The level of Centella asiatica present in the composition of the present invention may be 0.001%, 0.005% or preferably 0.01% by weight of the composition. The level of Centella asiatica present in the composition of the present invention may be less than 0.5%, more preferably less than 0.25%, and most preferably 0.1% by weight of the composition. In one embodiment, the level of Centella asiatica present in the composition of the present invention may be from 0.001 to 0.5% by weight of the composition. In one embodiment, the level of Centella asiatica present in the composition of the present invention may be from 0.005% to 0.25% by weight of the composition. In one embodiment, the level of Centella asiatica present in the composition of the present invention may be from 0.01% to 0.1% by weight of the composition.
[0021] Dipeptide
[0022] The composition of the present invention comprises a dipeptide selected from the group consisting of: acetyl dipeptide 1 cetyl ester (tyrosine-arginine), acetyl dipeptide 3 aminohexanoate (alanine-arginine), azelayl dipeptide 10 (alanine-histidine), coumaroyl dipeptide 3 (alanine-arginine), dicetyl dipeptide 9 (glutamic acid-lysine), dipeptide diaminobutyryl benzylamide diacetate, dipeptide 1 (tyrosine-arginine), dipeptide 10 (alanine-histidine), dipeptide 11 (cysteine), lysine), dipeptide 12 (lysine-lysine), dipeptide 14 (alanine-threonine), dipeptide 15 (glycine-glycine), dipeptide 16 (leucine-leucine), dipeptide 17 (glycine-proline), dipeptide 18 (glycine-histidine), dipeptide 19 (leucine-glutamic acid), dipeptide 2 (valine-tryptophan), dipeptide 20 (lysine-methionine), dipeptide 3 (alanine-arginine), dipeptide 4 (cysteine-glycine), dipeptide 5 (lysine Acid-valine), dipeptide 6 (proline-hydroxyproline), dipeptide 7 (lysine-threonine), dipeptide 8 (alanine-hydroxyproline), dipeptide 8HCL (alanine-hydroxyproline), dipeptide 9 (glutamic acid-lysine), hexanoyl dipeptide 3-norleucine acetate (alanine-arginine), methyl undecenoyl dipeptide 16 (leucine-leucine), nicotinyl dipeptide 22 (serine-valine), nicotinyl dipeptide 23 (proline-serine), nicotinyl dipeptide 24 (glutamic acid- threonine), nicotinyl dipeptide 26 (arginine-valine), oleoyl dipeptide 15 (glycine-glycine), palmitoyl dipeptide 10 (alanine-histidine), palmitoyl dipeptide 13 (tryptophan and glutamic acid), palmitoyl dipeptide 17 (glycine-proline), palmitoyl dipeptide 5 diaminobutyryl hydroxythreonine (lysine-valine), palmitoyl dipeptide 5 diaminohydroxybutyrate (lysine-valine), palmitoyl dipeptide 7 (lysine-threonine) and mixtures thereof.
[0023] The dipeptide is preferably incorporated into the emulsion of the present invention at a level of from 0.1 to 50,000 ppm, more preferably from 1 to 5,000 ppm, most preferably from 10 to 500 ppm.
[0024] Other components
[0025] The composition of the present invention can be aqueous or an emulsion, including a water-in-oil or an oil-in-water emulsion. When the composition is aqueous, it preferably comprises 60%, more preferably greater than 65% water. However, preferably, the composition is an emulsion. In one embodiment, the composition is an oil-in-water emulsion.
[0026] The aqueous phase of aqueous or emulsion preferably comprises a wetting agent, which can be selected from the group consisting of diols or triols. Preferred diols are those diols selected from the group consisting of pentylene glycol, caprylyl glycol, butylene glycol, dipropylene glycol, ethylhexylglycerol, propylene glycol, hexylene glycol, glycerol, butylene glycol, propylene glycol, isopentyl glycol, dipropylene glycol, pentylene glycol, hexylene glycol, polypropylene glycol, butylene glycol, polyethylene glycol, sorbitol, glucitol, mannitol, hydroxypropyl sorbitol, erythritol, threitol, pentaerythritol, xylitol and mixtures thereof. Preferred triols are those triols selected from the group consisting of hexanetriol, glycerine, ethoxylated glycerine, propoxylated glycerine and mixtures thereof.
[0027] When the composition is an emulsion, the oil phase of the emulsion may be provided by any suitable oily component. Suitable oils for the oil phase may include, for example: a) hydrocarbon oils such as paraffin or mineral oil; b) waxes such as beeswax or paraffin; c) natural oils such as sunflower seed oil, almond oil, shea butter or jojoba oil; d) silicone oils such as dimethicone, silicone elastomer, cyclomethicone or cetyl dimethicone; e) fatty acid esters and ethers such as isopropyl palmitate, isopropyl myristate, caprylic / capric triglyceride, C12-15 alkyl benzoate and polypropylene glycol-15 stearyl ether; f) fatty alcohols such as cetyl alcohol or stearyl alcohol; or g) mixtures thereof, for example blends of waxes commercially available under the trade name Cutina (BASF). Preferably, the emulsion comprises an oil phase of 0.1% to 55%, more preferably 5% to 25%, most preferably 10% to 20% by weight of the emulsion. Preferably, the oil phase of the emulsion comprises oil at a level of 50% to 99.9% by weight of the oil phase. More preferably, the oil phase comprises oil at a level of 60% to 99.9%, more preferably 70% to 99.9%, and even more preferably 80% to 99.9% by weight of the oil phase.
[0028] When the composition is a water-in-oil emulsion, it preferably includes an emulsifier. In a preferred embodiment, the composition includes 0.1% to 10% emulsifier by weight of the composition, more preferably 0.25% to 7.5%, and even more preferably 0.5% to 5% emulsifier. The emulsifier helps to disperse and suspend the oil phase in the water phase.
[0029] Silicone
[0030] Silicone is an optional ingredient of the composition. When present, the composition may include an organopolysiloxane oil. Suitable organopolysiloxane oils may be volatile, non-volatile, or a mixture of volatile and non-volatile silicones. The term "non-volatile" as used in this context refers to those silicones that are liquid or gel under ambient conditions and have a flash point (at one atmosphere) greater than 100° C. The term "volatile" as used in this context refers to all other silicone oils. Suitable organopolysiloxanes may be selected from various silicones having a wide range of volatility and viscosity. Examples of suitable organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes.
[0031] When present, preferred organopolysiloxanes for use herein are selected from polyalkylsiloxanes, alkyl-substituted polydimethylsiloxanes, cyclomethicone, trimethylsiloxysilicate, dimethiconol, polyalkylaryl siloxanes, and mixtures thereof. More preferred for use herein are polyalkylsiloxanes and cyclomethicone. Preferred among the polyalkylsiloxanes is polydimethylsiloxane.
[0032] Optionally, suitable silicones are silicone elastomers. Suitable silicone elastomers for use herein may be crosslinked siloxane elastomers or mixtures thereof that are emulsified or non-emulsified. There are no specific restrictions on the type of curable organopolysiloxane composition that can serve as the starting material for the crosslinked organopolysiloxane elastomer. Examples of this are addition reaction curing organopolysiloxane compositions that are cured by addition reactions between SiH-containing diorganopolysiloxanes and organopolysiloxanes having silicon-bonded vinyl groups under platinum metal catalysis; condensation curing organopolysiloxane compositions that are cured by dehydrogenation reactions between hydroxyl-terminated diorganopolysiloxanes and SiH-containing diorganopolysiloxanes in the presence of organotin compounds, and condensation curing organopolysiloxane compositions that are cured in the presence of organotin compounds or titanates.
[0033] When the composition is in the form of an emulsion, the oil phase comprises silicone, and most preferably a silicone elastomer.Preferably, the emulsion composition comprises from 20% to 35% of the silicone elastomer raw material by weight of the emulsion composition.
[0034] Ceramide
[0035] Ceramides are a family of waxy lipid molecules. Ceramides are composed of sphingosine and fatty acids. In an optional embodiment of the present invention, the composition includes at least one ceramide. Without being limited by theory, the ceramide may be selected from the group consisting of: ceramide 1 (ceramide EOP), ceramide 2 (ceramide NG), ceramide 3 (ceramide NP) and / or ceramide 6 (ceramide AP). The above ceramides are well known in the art and defined by this nomenclature. However, to avoid ambiguity: ceramide 1 (ceramide EOS)-includes a sphingosine base and a non-hydroxy fatty acid chain connected to linoleic acid; ceramide 2 (ceramide NS) includes a sphingosine base and a non-hydroxy fatty acid chain; ceramide 3 (ceramide NP) includes a phytosphingosine base (an OH group at the C4 position on the sphingosine base molecule) and a non-hydroxy fatty acid chain; ceramide 6 (ceramide AP) includes a phytosphingosine base (an OH group at the C4 position on the sphingosine base molecule) and an α-hydroxy fatty acid chain (an additional OH group on the fatty acid relative to the non-hydroxyl group).
[0036] In a preferred aspect of the invention, the composition preferably comprises ceramide 3 (ceramide NP), also known as N-oleoyl-4-hydroxydihydrosphingosine. In a further preferred but optional aspect of the invention, the composition preferably comprises ceramide 6 (ceramide AP).
[0037] Alternatively, the composition may include at least two ceramides, such as ceramide 3 and ceramide 6. Alternatively, the composition may include at least three ceramides, such as ceramide 1, ceramide 3, and ceramide 6.
[0038] In one embodiment of the present invention, the ceramide is Skinmimic (trade name) commercially available from Evonik. Skinmimic is an ingredient comprising a plurality of ceramides including ceramide EOP, ceramide EOS, ceramide NP, ceramide NS, ceramide AP, hexanoyl phytosphingosine and hexanoyl sphingosine.
[0039] When present, the amount of ceramide present in the composition (e.g., the amount of ceramides alone or in combination) can be at least 0.003%, at least 0.005%, at least 0.008%, or at least 0.01% by weight; and / or the amount of at least one ceramide present in the composition (e.g., the combined amount of Ceramides 1, 3, and 6) can be 0.1% or less, 0.05% or less, 0.03% or less, or 0.01% or less by weight.
[0040] When present, the amount of ceramide present in the composition (eg, the amount of ceramides alone or in combination) may be 0.003% to 0.03% or 0.005% to 0.02% by weight.
[0041] Antioxidants
[0042] The compositions of the present invention may optionally include an antioxidant. Suitable antioxidants may include: a) ascorbic acid and its salts, esters, glucosides and glucosamines, in particular sodium ascorbyl phosphate, magnesium ascorbyl phosphate and ascorbyl palmitate b) vitamin E (tocopherol) and its esters, in particular tocopheryl acetate, and dimethylmethoxychromanol, which is a synthetic analogue of gamma-tocopherol, available from Lipotec SApolygon Industrial Camri Ral under the trade name Lipochroman-6, c) herbal extracts, in particular gingko biloba, such as available from Univar PLC under the trade name "Gingko Biloba Leaf Powder", morus alba, such as available from Solabia under the trade name "Mulberry Concentrate", origanum vulgare, such as available from S Black Ltd under the trade name "Pronalen Origanum HSC", panax ginseng, such as available from S Black Ltd under the trade name "Panax ginseng 1.1 extract 4294" or available from Croda Chemicals Ltd under the trade name "Phytexcell Panax ginseng", birch extracts such as available from Cosmetochem (UK) Ltd under the trade names "SuperHerbasol Extract Birch" and "HP Herbasol Betula" and from Blagden Chemicals under the trade names "Phytelene of Birch" and "Aqueous Spray Dried Birch", tea (camellia sinensis), such as available from Nichimen Europe under the trade name "Herbal Extract Green Tea 75% Solids", rosemary (rosmarrinus officinalis), such as available from S. Black under the trade name "Pronalen Rosemary", acerola powder, such as available from Gee Lawson as Acerola PE, emblica extract, available from Merck Specialitychemicals under the trade name Emblica TMSold as well as grapeseed oil, such as available from Chesham Chemicals Limited.
[0043] The source of the antioxidant activity of some of these agents is often not completely clear; for example, it is believed that the antioxidant activity of Ginkgo extracts originates from the presence of flavonglycocide and / or terpene lactones, which can be free radical inhibitors. Birch extracts can be produced by extracting the dried leaves of Betula alba with a suitable solvent. It is believed that the anti-free radical activity of birch extracts is due to the presence of flavonoids, such as hyperosid, quencitrosid and / or myricetol-3digalactosid, which can be free radical inhibitors. These products are usually sold in the form of mixtures or solutions.
[0044] Thus, the antioxidant may consist of a number of active ingredients that are free radical inhibitors, or may also include suitable diluents and / or carriers (such as when the anti-free radical agent is some of the products mentioned herein). Therefore, the actual level of the agent in commercially available products may be somewhat unclear. Therefore, as will be appreciated by those skilled in the art, the amount of antioxidant used in the present invention is expressed in dry weight. The total amount of antioxidant present in the composition may range from 0.005% to 10%, preferably from 0.5% to 5%, and most preferably from 1% to 3.5% by weight of the composition.
[0045] Particularly preferred synergistic combinations of antioxidants suitable for inclusion in the skin care compositions of the present invention are: ginseng, mulberry and magnesium ascorbyl phosphate; ginseng, mulberry and sodium ascorbyl phosphate; ginseng, mulberry and rosemary; ginseng, mulberry and oregano.
[0046] In these preferred combinations, (a) ginseng is preferably present in an amount of 0.005% to 0.1%, more preferably 0.01% to 0.05% by weight of the composition; (b) mulberry is preferably present in an amount of 0.0005% to 0.01%, more preferably 0.001% to 0.005% by weight of the composition; (c) sodium ascorbyl phosphate or magnesium ascorbyl phosphate is preferably present in an amount of 0.05% to 2.5%, preferably 0.1% to 2%, most preferably 0.15% to 1.5% by weight of the composition, and (d) rosemary or oregano is preferably present in an amount of 0.01% to 0.5%, more preferably 0.05% to 0.2% by weight of the composition.
[0047] When an antioxidant is described as a plant extract, the weight incorporated into the composition is based on the weight of the raw product as received from the supplier and not on the weight of the active antioxidant component of the raw product.
[0048] Monocyclic sesquiterpene alcohol
[0049] The composition may include sesquiterpene alcohols. Sesquiterpenes are a class of terpenes composed of three isoprene units and generally have a molecular formula of C 15 H 24 . Sesquiterpenes can be acyclic or contain rings. The present invention can additionally employ alcohol derivatives of monocyclic (single ring) sesquiterpenes. For example, the monocyclic sesquiterpene alcohol can be α-bisabolol (shown in the figure below, left) or β-bisabolol (shown in the figure below, right). Synthetic bisabolol is usually a racemic mixture: α-(±)-bisabolol
[0050]
[0051] The amount of monocyclic sesquiterpene alcohol (e.g., α-bisabolol) present in the composition may be at least 0.001%, at least 0.5%, more preferably at least 0.01%, at least 0.05%, at least 0.1% by weight; and / or the amount of monocyclic sesquiterpene alcohol (e.g., α-bisabolol) present in the composition may be 2% or less, 1% or less, 0.5% or less by weight.
[0052] Specifically, the amount of monocyclic sesquiterpene alcohol (eg, α-bisabolol) present in the composition may be 0.001% to 2%, 0.01% to 1%, or 0.05% to 0.5% by weight.
[0053] Emulsifier
[0054] The composition of the invention may include an emulsifier. Suitable emulsifiers include all those emulsifiers suitable for the purpose and known to those skilled in the art for use in skin care products. Preferably, these emulsifiers have an HLB value of 5 or more, more preferably from 5 to 17, and even more preferably from 10 to 17.
[0055] Among the emulsifiers that can be used herein are various nonionic and anionic emulsifiers, such as sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated derivatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglycerol esters of C1-C30 fatty acids, C1-C30 esters of polyols, C1-C30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, and mixtures thereof. Non-limiting preferred examples of these non-silicone emulsifiers include: polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, steareth-20, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG -100 Stearate, Polyoxyethylene 20 Sorbitan Trioleate (Polysorbate 85), Sorbitan Monolaurate, Polyoxyethylene 4 Lauryl Ether Sodium Stearate, Polyglyceryl-4 Isostearate, Hexyl Laurate, Steareth-20, Ceteareth-20, PPG-2 Methyl Glucose Ether Distearate, Ceteth-10, Diethanolamine Cetyl Phosphate, Glyceryl Stearate, PEG-100 Stearate and mixtures thereof.
[0056] Other peptides
[0057] The composition of the present invention may also include a peptide. Preferably, the additional peptide is selected from the group consisting of a tripeptide, a tetrapeptide, a pentapeptide and mixtures thereof. A tripeptide means a compound comprising an uninterrupted sequence of three amino acids. A tetrapeptide means a compound comprising an uninterrupted sequence of four amino acids. A pentapeptide means a compound comprising an uninterrupted sequence of five amino acids.
[0058] Tripeptide:
[0059] The emulsion of the present invention preferably comprises a tripeptide. The tripeptide may be naturally occurring or synthetically derived. Suitable tripeptides include tripeptides 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, derivatives thereof, and mixtures thereof.
[0060] Particularly preferred tripeptides include one or more tripeptides based on His. However, another suitable tripeptide can be Arg-Lys-Arg. Particularly preferred tripeptides are based on the structure Gly-His-Lys and its analogs and derivatives thereof. These are collectively referred to as GHK-tripeptides in this article. In fact, the preferred tripeptides according to this aspect of the present invention have this precise amino acid sequence. The analogs of the preferred tripeptides that can be used herein include one or more analogs of the three amino acids that are reorganized or rearranged in the sequence (e.g., Gly-Lys-His) and / or those in which no more than two amino acids are replaced (e.g., His-Ala-Orn). However, most preferably, the amino acid replacing Gly includes aliphatic side chains such as, but not limited to, β-Ala, Ala, Val, Leu, Pro, sarcosine (Sar) and Ile. Most preferably, Ala, Leu and Ile. The most preferred amino acids replacing Lys or His include amino acids having side chains comprising predominantly charged nitrogen at pH 6, such as, but not limited to, Pro, Lys, Arg, His, desmosine, and isodesmosine. Most preferably, Lys is replaced by Orn, Arg, or citrulline.
[0061] Derivatives are also considered to be included in the term GHK-tripeptide according to the present invention (and therefore also include the more general term tripeptide). Derivatives of the GHK-tripeptide according to the present invention include derivatives of the displacement and rearrangement of the tripeptide described herein. These derivatives especially include acyl derivatives, which are tripeptides substituted with the following: one or more straight or branched chains, long or short chains, saturated or unsaturated, substituted or unsubstituted with hydroxyl, amino, acylamino, sulfate or sulfide groups, which can be derived from acetic acid, capric acid, lauric acid, myristic acid, caprylic acid, palmitic acid, stearic acid, behenic acid, linoleic acid, linolenic acid, lipoic acid, oleic acid, isostearic acid, elaidic acid, 2-ethylhexanoic acid, coconut oil fatty acid, tallow fatty acid, hardened tallow fatty acid, palm kernel oil fatty acid, lanolin fatty acid, etc. Preferred examples of acyl groups include acetyl groups, palmitoyl groups, elaidoyl groups, myristyl groups, biotinyl groups and capryl groups. These can be substituted or unsubstituted. When substituted, they are preferably substituted with hydroxyl or sulfur-containing groups such as, but not limited to, SO 3 H, SH or SS.
[0062] The tripeptide based on His includes at least one histidine amino acid. The other two amino acids in the sequence can be the same or different. Therefore, it is encompassed but not limited to His-Xaa-Xaa, His-Xaa-Xbb, His-Xbb-Xaa, Xbb-His-Xbb, Xbb-His-Xaa, Xaa-His-Xbb, Xaa-Xaa-His, Xaa-Xbb-His, Xbb-Xaa-His and Xbb-Xbb-His, wherein Xaa and Xbb are two different amino acids, but any one of them can be His. Preferably, at least one of the other amino acids is Gly, β-Ala, Ala, Val, Leu, Pro, sarcosine (Sar) or Ile. Preferably, at least one of the other amino acids is Pro, Lys, Arg, His, desmosine and isodesmosine. Most preferably, Lys is replaced by Orn, Arg or citrulline.
[0063] Derivatives are also considered to be encompassed in the term His-based tripeptides according to the invention (and therefore also the more general term tripeptides). These derivatives include in particular acyl derivatives, which are tripeptides substituted with one or more linear or branched, long or short chain, saturated or unsaturated, substituted or unsubstituted acyl groups having 1 to 29 carbon atoms. The acyl groups that can be used are the same as those described for the GHK-tripeptide.
[0064] Particularly preferred embodiments of the tripeptides according to the present invention include N-acyl-Gly-His-Lys and most preferably, N-palmitoyl-Gly-His-Lys. Preferred commercially available compositions including tripeptides and tripeptide derivatives include Biopeptide-CL from SEDERMA, Maxilip (R) from SEDERMA, Biobustyl (R) from SEDERMA.
[0065] The tripeptides of the present invention are preferably used in amounts as low as 0.10 ppm to 10,000 ppm, preferably 0.50 ppm to 5,000 ppm, more preferably 1 ppm to 1000 ppm, and most preferably 1 ppm to 500 ppm. These are also based on a % w / w basis. Thus, 100,000 ppm is 10% by weight of the emulsion.
[0066] Tetrapeptide:
[0067] The emulsion of the present invention preferably comprises a tetrapeptide. These may be one or more rigin-based tetrapeptides, one or more ALAMCAT-tetrapeptides or mixtures thereof. These tetrapeptides may be naturally occurring or synthetic in origin. Suitable tetrapeptides for use in the present composition include those selected from the group consisting of: tetrapeptide 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 34, 35, derivatives thereof and mixtures thereof.
[0068] The tetrapeptides based on Rigin according to the present invention are based on the structure Gly-Gln-Pro-Arg (Rigin) and include analogs and derivatives thereof. Rigin is a preferred tetrapeptide. Analogs of tetrapeptide sources useful according to the present invention include those in which one or more of the four amino acids are reorganized or rearranged within the sequence and / or in which no more than two amino acids are replaced (e.g., Ala-Gln-Thr-Arg. More preferably, at least one amino acid within the sequence is Pro or Arg, and most preferably, the tetrapeptide includes both Pro and Arg, although their order and position may be different. Amino acid replacements can be from any amino acid defined herein. Particularly preferred tetrapeptides based on Rigin include Xaa-Xbb-Arg-Xcc, Xaa-Xbb-Xcc-Pro, Xaa-Xbb-P ro-Arg, wherein Xaa-Xbb-Pro-Xcc, Xaa-Xbb-Xcc-Arg, Xaa, Xbb and Xcc may be the same or different and are selected from the following: Xaa is Gly or an amino acid that can be replaced thereby, Xbb is Gln or an amino acid that can be replaced thereby, and Xcc may be Pro or Arg or an amino acid that can be replaced thereby. The most preferred amino acids replacing Gly include aliphatic side chains such as, but not limited to, β-Ala, Ala, Val, Leu, Pro, sarcosine (Sar) and Ile. The most preferred amino acids replacing Gln include side chains containing mainly uncharged amine groups at neutral pH (pH 6-7), such as, but not limited to, Asn, Lys, Orn, 5-hydroxyproline, citrulline and canavanine. When Arg is replaced, it is preferably replaced by amino acids having side chains that mainly include charged nitrogen at pH 6, such as, but not limited to, Pro, Lys, His, desmosine and isodesmosine.
[0069] Derivatives are also considered to be encompassed by the term rigin-based tetrapeptides according to the present invention (and therefore also the more general term tetrapeptides). Derivatives include substituted and rearranged derivatives of the rigin-based tetrapeptides described herein. These derivatives include in particular acyl derivatives, which are tetrapeptides substituted with one or more linear or branched, long or short chain, saturated or unsaturated, substituted with hydroxyl, amino, aminoacyl, sulfate or sulfide groups or unsubstituted with 1 to 29 carbon atoms. N-acyl derivatives include acyl groups derivable from acetic acid, capric acid, lauric acid, myristic acid, caprylic acid, palmitic acid, stearic acid, behenic acid, linoleic acid, linolenic acid, lipoic acid, oleic acid, isostearic acid, elaidic acid, 2-ethylhexanoic acid, coconut oil fatty acids, tallow fatty acids, hardened tallow fatty acids, palm kernel oil fatty acids, lanolin fatty acids, etc. Preferred examples of acyl groups include acetyl groups, palmitoyl groups, elaidoyl groups, myristyl groups, biotinyl groups and octanoyl groups. These can be substituted or unsubstituted. When substituted, they are preferably substituted by hydroxyl or groups including sulphur such as but not limited to SO3H, SH or SS.
[0070] ALAMCAT tetrapeptides are tetrapeptides comprising at least one amino acid comprising a side chain containing an aliphatic group. These amino acids include, but are not limited to, Gly, β-Ala, Ala, Val, Leu, Sarcosine (Sar), and Ile. These tetrapeptides also include at least one amino acid comprising at least one side chain containing NH2. These amino acids include side chains having amine groups that are primarily uncharged at neutral pH (pH 6-7), such as, but not limited to, Gln, Asn, Lys, Orn, 5-hydroxyproline, citrulline, and canavanine. ALAMCAT-tetrapeptides also include at least one amino acid having at least one side chain comprising at least one cationic amine (the primary species being charged, such as NH3+, NH2+, etc. - basic amino acids that are positively charged at pH 6.0). These amino acids include, but are not limited to, Pro, Arg, Lys, His, desmosine, and isodesmosine. The remaining amino acids may be any amino acid, but are preferably amino acids comprising an aliphatic group, a side amino group, or a side cationic group. According to the invention, derivatives are also considered to be encompassed by the term ALAMCAT-tetrapeptide (and therefore also the more general term tetrapeptide). These derivatives include in particular acyl derivatives, which are tetrapeptides substituted with one or more linear or branched, substituted or unsubstituted long or short chain, saturated or unsaturated acyl groups having 1 to 29 carbon atoms. The acyl groups that can be used are the same as those described for the rigin-based tetrapeptides.
[0071] Preferred embodiments include peptide E, arg-ser-arg-lys, N-acyl-Gly-Gln-Pro-Arg peptides, most preferably N-palmitoyl-Gly-Gln-Pro-Arg.
[0072] Preferred commercial tetrapeptide sources include RIGIN, EYELISS, Haloxyl and MATRIXYL 3000, which includes 50 to 500 ppm of palmitoyl-Gly-Gln-Pro-Arg, and other ingredients such as peptides, chalcone and excipients, commercially available from SEDERMA, France. Tego Pep 417 is available from Evonik. These can be used to produce the compositions of the present invention by adding thereto at least one tripeptide as described herein.
[0073] The tetrapeptide, when present (eg, a lipopeptide), may have an amino acid sequence selected from the group consisting of: (i) GPXG, (ii) LSXX, (iii) XXGD, or (iv) QTAV
[0074] wherein, for (i), G represents the amino acid glycine and P represents the amino acid proline (according to the internationally recognized single-letter code for amino acids), and X represents an amino acid selected from the group consisting of lysine (K), glutamic acid (E) and serine (S), and mixtures thereof, wherein, for (ii), L represents the amino acid leucine and S represents the amino acid serine (according to the internationally recognized single-letter code for amino acids), and X represents an amino acid selected from the group consisting of valine (V), aspartic acid (D), proline (P), glycine (G), and mixtures thereof, wherein, for (iii), G represents the amino acid glycine and D represents the amino acid aspartic acid (according to the internationally recognized single-letter code for amino acids), and X represents an amino acid selected from the group consisting of glutamic acid (E), lysine (K), leucine (L), alanine (A), isoleucine (I), arginine (R), and mixtures thereof, and for (iv), Q represents the amino acid glutamine, T represents the amino acid threonine, A represents the amino acid alanine, and V represents the amino acid valine.
[0075] In another embodiment, the peptide (e.g., lipopeptide) has an amino acid sequence selected from the group consisting of: (i) Y-GPXG-Z, (ii) Y-LSXX-Z, (iii) Y-XXGD-Z or (iv) Y-QTAV-Z, wherein, for (i), G represents the amino acid glycine and P represents the amino acid proline (according to the internationally recognized single-letter code for amino acids), and X represents an amino acid selected from the group consisting of lysine (K), glutamic acid (E) and serine (S), and mixtures thereof, wherein, for (ii), L represents the amino acid leucine and S represents the amino acid serine (according to the internationally recognized single-letter code for amino acids), and X represents an amino acid selected from the group consisting of An amino acid selected from the group consisting of valine (V), aspartic acid (D), proline (P), glycine (G), and mixtures thereof, wherein, for (iii), G represents the amino acid glycine and D represents the amino acid aspartic acid (according to the internationally recognized single-letter code for amino acids), and X represents an amino acid selected from the group consisting of glutamic acid (E), lysine (K), leucine (L), alanine (A), isoleucine (I), arginine (R), and mixtures thereof, wherein, for (iv), Q represents the amino acid glutamine, T represents the amino acid threonine, A represents the amino acid alanine, and V represents the amino acid valine, and wherein, at the N-terminus, Y is selected from the group consisting of H, -CO-R 1 、-SO 2 -R 1 or a biotinyl group, at the C-terminus, Z is selected from OH, OR 1 、NHR 1 or NR 1 R 2 Composed of groups.
[0076] In one embodiment, R 1 and R 2 Independently selected from the group consisting of alkyl, aryl, aralkyl, alkylaryl, alkoxy, sugar and aryloxy groups, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonylated, phosphorylated and / or sulfur-containing, said groups comprising 1 to 24 carbon atoms and being able to include one or more heteroatoms O, S and / or N.
[0077] In a preferred embodiment of the invention, the tetrapeptide is modified at the N-terminus and / or the C-terminus.
[0078] In a preferred embodiment, the tetrapeptide of the present invention is selected from the group consisting of: Y-EKGD-Z, Y-ELGD-Z, Y-EAGD-Z, Y-EIGD-Z, Y-ERGD-Z, Y-KEGD-Z, Y-KLGD-Z, Y-KAGD-Z, Y-KIGD-Z, Y-KRGD-Z, Y-LEGD-Z, Y-LKGD-Z, Y-LAGD-Z, Y-LIGD-Z In another embodiment, the tetrapeptide is selected from the group consisting of Y-EKGD-Z, Y-LKGD-Z, Y-IRGD-Z, and Y-AKGD-Z. In another embodiment, the tetrapeptide is Y-EKGD-Z. In another embodiment, the tetrapeptide is Y-LKGD-Z. In another embodiment, the tetrapeptide is Y-IRGD-Z. In another embodiment, the tetrapeptide is Y-AKGD-Z.
[0079] In a preferred embodiment of the tetrapeptide combination of the present invention, the tetrapeptide a) is selected from the group consisting of: Y-LSVD-Z, Y-LSVP-Z, Y-LSVG-Z, Y-LSDV-Z, Y-LSDP-Z, Y-LSDG-Z, Y-LSPV-Z, Y-LSPD-Z, Y-LSPG-Z, Y-LSGV-Z, Y-LSGD-Z and Y-LSGP-Z. In another embodiment, the tetrapeptide is selected from the group consisting of Y-LSVD-Z, Y-LSPG-Z and Y-LSPD-Z. In another embodiment, the tetrapeptide is Pal-LSVD-OH. In another embodiment, the tetrapeptide is Pal-LSPG-OH. In another embodiment, the tetrapeptide is Pal-LSPD-OH.
[0080] In a further preferred embodiment of the present invention, the tetrapeptide is Y-GPKG-Z. In a further preferred embodiment of the present invention, the tetrapeptide is Y-GPEG-Z. In a further preferred embodiment of the present invention, the tetrapeptide is Y-GPSG-Z.
[0081] The tetrapeptides of the present invention are preferably used in amounts of 0.1 ppm (0.00001% w / w, also referred to herein as "weight percent," "weight %" or simply by weight) to 10,000 ppm (0.5% w / w) by weight of the composition, preferably 0.5 ppm to 1000 ppm (0.05% w / w) and most preferably 1 ppm to 500 ppm.
[0082] The combination of tripeptides and tetrapeptides is particularly preferred. The preferred ratio of tetrapeptides to tripeptides, or indeed the ratio of molecules with four amino acids to molecules with three amino acids, can be in the range of 100:1 to 1:100; more preferably 50:1 to 1:50, even more preferably 30:1 to 1:30, and even more preferably between 10:1 and 1:10. Most preferably, the ratio of tetrapeptides to tripeptides ranges from 3:1 to 1:3. These ratios are based on weight (% w / w - for example mg of pure peptide per kilogram in the final formulation). In a particularly preferred embodiment, again based on the total weight of the composition, the amount of tripeptides used is greater than the amount of tetrapeptides used when considering their amounts in parts per million. In a particularly preferred embodiment, the emulsion of the present invention comprises a combination of tetrapeptides of the sequence Gly-Gln-Pro-Arg, analogs and derivatives thereof and one or more tripeptides of the sequence Gly-His-Lys, analogs and derivatives thereof.
[0083] Pentapeptide
[0084] The compositions of the present invention may optionally include pentapeptides, pentapeptide derivatives, and mixtures thereof. As used herein, "pentapeptide" refers to naturally occurring pentapeptides and synthetic pentapeptides. Also useful herein are naturally occurring and commercially available compositions comprising pentapeptides. Suitable pentapeptides are those selected from the group consisting of: pentapeptide 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 33, 34, 35, 36, 38, 39, derivatives thereof, and mixtures thereof.
[0085] Suitable pentapeptides for use herein are the pentapeptides lys-thr-thr-lys-ser, Arg-asp-lys-tyr-val (pentapeptide-1) and derivatives thereof. A preferred commercially available composition comprising a pentapeptide derivative is Matrixyl, which comprises 100 ppm of palmitoyl-lys-thr-thr-lys-ser and is commercially available from Sederma, France.
[0086] The pentapeptide and / or pentapeptide derivative, when present, is preferably included in the emulsion in an amount of from 0.01% to 20%, more preferably from 0.05% to 15%, and even more preferably from 0.1% to 10% by weight of the composition.
[0087] Matrix metalloproteinase inhibitors (MMPi)
[0088] The composition of the present invention may include a matrix metalloproteinase inhibitor. The term "matrix metalloproteinase inhibitor" refers to all molecules and / or plant or bacterial extracts that have inhibitory activity on at least one of the matrix metalloproteinases expressed or synthesized by or in the skin. The matrix metalloproteinase family is formed by several well-defined groups, based on their similarities in structure and substrate specificity (Woessner JF, Faseb Journal, vol. 5, 1991, 2145). Among these groups, there are collagenases capable of degrading fibrillar collagen (MMP-1 or interstitial collagenase, MMP-8 or neutrophil collagenase, MMP-13 or collagenase 3, MMP-18 or collagenase 4), gelatinases that degrade type IV collagen or other denatured collagen forms (MMP-2 or A gelatinase (72 kDa), MMP-9 or B gelatinase (92 kDa)), stromelysins (MMP-3 or stromelysin 1, MMP-10 or stromelysin 2, MMP-11 or stromelysin 3), whose broad spectrum of activity targets proteins of the extracellular matrix, such as glycoproteins (fibronectin, laminin), proteoglycans, etc., stromelysins (MMP-7), metalloelastases (MMP-12) or metalloproteinases (MMP-14, MMP-15, MMP-16 and MMP-17). Metalloproteinases (MMPs) are proteases that use metals (mainly zinc) to coordinate with three cysteine residues and methionine in their active sites, which can degrade the macromolecular components of the extracellular matrix and the basal layer (collagen, elastin, etc. ...) at neutral pH. This group of enzymes is inactivated by metal chelators. The main activity regulators of MMPs are tissue inhibitors of metalloproteinases or TIMPs such as TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (Woessner JF, Faseb Journal, 1991). In addition, MMP expression is also regulated by growth factors, cytokines, oncogene products (ras, jun) or matrix components.
[0089] According to the present invention, the term "matrix metalloproteinase inhibitor" means all molecules that are capable of reducing MMP activity with respect to gene expression (transcription and translation) or with respect to activation of the MMP zymogen form or with respect to local control of the active form. In addition, the metalloproteinase inhibitor according to the present invention can also be an MMP-1 inhibitor of natural or synthetic origin. The term "natural origin" or "synthetic origin" means a metalloproteinase inhibitor in a pure state or in a solution of different concentrations, but the inhibitors referred to as natural origin are obtained from natural elements (e.g. lycopene in tomatoes) by different extraction methods, while inhibitors of synthetic origin are all obtained via chemical synthesis.
[0090] Preferred MMPi are selected from the group consisting of retinoids, N-acetylcysteine, glutathione, 2-furildioxime, vitamin C, flavonoids, isoflavones, hydrolyzed rice protein, alfalfa extract, white lupin, zizyphus jujube extract, dihydroxymethylchromone, kudzu extract, vitis vinifera extract, evening primrose extract, Anogeissus leiocarpus extract, and mixtures thereof.
[0091] When present, the MMPi is present at a level of from 0.01% to 10%, more preferably from 0.1% to 5%, and most preferably from 1% to 2.5% by weight of the composition.
[0092] Skin Conditioners
[0093] The composition of the present invention may optionally include a skin conditioning agent. The skin conditioning agent may preferably be selected from the group consisting of a moisturizer, an emollient, a moisturizer or mixtures thereof. If present, they are preferably present at a level of 0.01% to 20%, more preferably 0.1% to 10%, most preferably 0.5% to 7% by weight of the emulsion.
[0094] Preferred skin conditioning agents are selected from the group consisting of guanidine, urea, glycolic acid and glycolate salts, salicylic acid, lactic acid and lactate salts, aloe vera, shea butter, polyhydroxy alcohols such as sorbitol, mannitol, xylitol, erythritol, glycerol, hexanetriol, butanetriol, (di)propylene glycol, butylene glycol, hexylene glycol, polyethylene glycol, sugars (e.g. fructose, glucose, xylose, honey, mannose, xylose), gluconolactone and starch and its derivatives, pyrrolidones, carboxylic acids, hyaluronic acid and its salts, lactamide monoethanolamine, acetamide monoethanolamine, panthenol, allantoin and mixtures thereof.
[0095] The composition may include hyaluronic acid or a salt thereof, such as sodium hyaluronate or potassium hyaluronate. The composition preferably includes sodium hyaluronate.
[0096] Specifically, the amount of hyaluronic acid or a salt thereof (eg, sodium hyaluronate) present in the composition may be 0.01% to 0.2% or 0.03% to 0.1% by weight.
[0097] More preferably, the skin conditioning agent is selected from glycerin, arabinogalactan, butylene glycol, hyaluronic acid, shea butter, propylene glycol, ethylhexylglycerin and hyaluronate.
[0098] Vitamins
[0099] The composition of the present invention may include one or more vitamins. The composition may include ascorbic acid, such as vitamin C, vitamin C derivatives, ascorbic acid, ascorbyl glucoside, ascorbyl palmitate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate. The composition may include vitamin B, vitamin B derivatives, vitamin B1 to vitamin B12 and derivatives thereof, vitamin K, vitamin K derivatives, vitamin H, vitamin D, vitamin D derivatives, vitamin E, vitamin E derivatives such as tocopherol and tocopherol acetate, and provitamins such as panthenol and mixtures thereof. Vitamin compounds may be included as substantially pure materials or as extracts obtained from natural (e.g., plant) sources by appropriate physical and / or chemical separation. In one embodiment, when vitamin compounds are present in the composition of the present invention, the composition includes vitamin compounds of about 0.0001% to 50%, more preferably 0.001% to 10%, still more preferably 0.01% to 8%, and still more preferably 0.1% to 5% by weight of the composition.
[0100] In a preferred alternative embodiment, the composition may additionally include vitamin B (e.g., vitamin B1 to vitamin B12) or a vitamin B derivative (e.g., a derivative of vitamin B1 to vitamin B12 such as vitamin B3). In particular, the composition may include a vitamin B3 compound such as niacinamide.
[0101] Vitamin B3 and niacin are the common names for nicotinic acid. The physiologically active form of niacin is nicotinamide. Nicotinic acid and nicotinamide (nicotinamide or nicotinic acidamide) function in the body as components of the following two coenzymes: nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP).
[0102] The composition used in the present invention may include a safe and effective amount of a (natural or synthetic) vitamin B3 compound. As used herein, "vitamin B3 compound" means a compound having the formula:
[0103]
[0104] Where R is -CONH 2 (i.e., nicotinamide), -COOH (i.e., nicotinic acid), or -CH 2 OH (ie, nicotinic alcohol); derivatives thereof; and salts of any of the foregoing.
[0105] Exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid, nicotinyl amino acid, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide, and nicotinamide N-oxide.
[0106] Suitable nicotinic acid esters include nicotinic acid esters of C1-C22, preferably C1-C16, more preferably C1-C6 alcohols. The alcohol may be linear or branched, cyclic or acyclic, saturated or unsaturated (including aromatic) and substituted or unsubstituted. Preferred esters are those that do not produce a visible flushing reaction after application to the skin. Alternatively, nicotinic acid substances that do produce a flushing reaction may be used if used in lower doses to reduce the flushing effect. Non-flushing nicotinic acid esters include tocopherol nicotinate and inositol hexanicotinate. Tocopherol nicotinate is preferred.
[0107] Other derivatives of vitamin B3 compounds are derivatives of nicotinamide resulting from substitution of one or more amide group hydrogens. Non-limiting examples of derivatives of nicotinamide useful herein include nicotinyl amino acids derived, for example, from the reaction of activated nicotinic acid compounds (e.g., nicotinic acid azide or nicotinyl chloride) with amino acids, and nicotinyl alcohol esters of organic carboxylic acids (e.g., C1-C18). Specific examples of such derivatives include nicotinylglycine and nicotinylhydroxamic acid.
[0108] Exemplary nicotinic alcohol esters include nicotinic alcohol esters of carboxylic acids including salicylic acid, acetic acid, glycolic acid, palmitic acid, etc. Other suitable vitamin B3 compounds are selected from the group consisting of 2-chloronicotinamide, 6-aminonicotinamide, 6-methylnicotinamide, n-methyl-nicotinamide, n,n-diethylnicotinamide, n-(hydroxymethyl)-nicotinamide, quinolinic acid imide, nicotinanilide, n-benzylnicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methylisonicotinic acid, thionicotinamide, nialamide, 1-(3-pyridylmethyl)urea, 2-mercaptonicotinic acid, nicomol, niaprazine, and mixtures thereof.
[0109] Examples of the above vitamin B3 compounds are well known in the art and are commercially available from a number of sources, for example, Sigma Chemical Company (St. Louis, MO); ICN Biomedicals, Inc. (Irvin, CA); and Aldrich Chemical Company (Milwaukee, WI).
[0110] The compositions of the present invention preferably include one or more vitamin B3 compounds. Preferred vitamin B3 compounds are niacinamide and tocopheryl nicotinate. Niacinamide is more preferred.
[0111] Salts of vitamin B3 compounds are also useful herein. Non-limiting examples of salts of vitamin B3 compounds useful herein include organic or inorganic salts, such as inorganic salts with anionic inorganic species (e.g., chlorides, bromides, iodides, carbonates, preferably chlorides), and organic carboxylates (including mono-C1-C18 carboxylates, di-C1-C18 carboxylates, and tri-C1-C18 carboxylates, e.g., acetates, salicylates, glycolates, lactates, malates, citrates, preferably mono-carboxylates, such as acetates).
[0112] The vitamin B3 compound may be included as the substantially pure material, or as an extract isolated from a natural source by suitable physical and / or chemical methods. The vitamin B3 compound is preferably substantially pure, more preferably essentially pure.
[0113] The amount of vitamin B or vitamin B derivative (e.g., vitamin B3 compound, such as niacinamide) present in the composition may be at least 0.01%, at least 0.05%, at least 0.1%, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight; and / or the amount of vitamin B or vitamin B derivative (e.g., vitamin B3 compound, such as niacinamide) present in the composition may be 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.5% or less, 0.1% or less, or 0.05% or less by weight. When more than one vitamin B / vitamin B derivative is present, these values apply to the total amount of vitamin B or vitamin B derivative.
[0114] Specifically, the amount of vitamin B or a vitamin B derivative (e.g., niacinamide) present in the composition may be 0.01 to 5%, 0.05% to 3%, 0.1% to 3%, 0.1% to 2%, 0.5% to 1%, or 0.5% to 2% by weight.
[0115] Other optional ingredients
[0116] The composition of the present invention may also optionally include one or more of the following optional ingredients. Preservatives may be added to the emulsion, such as 2-bromo-2-nitropropane-1,3-diol (bronopol, which is commercially available under the trade name Myacide RTM), benzyl alcohol, bis(hydroxymethyl)imidazolidinyl urea, imidazolidinyl urea, methylparaben, phenoxyethanol, ethylparaben, propylparaben, sodium methylparaben, sodium dehydroacetate, polyhexamethylene biguanide hydrochloride, isothiazolones and sodium propylparaben, suitably in an amount of 0.01% to 10% by weight of the emulsion.
[0117] Thickeners, viscosity modifiers and / or gelling agents may be added to the composition, such as acrylic acid polymers, for example commercially available under the trade names Carbopol, Pemulen or Ultrez (Lubrizol), or modified celluloses, for example hydroxyethylcellulose (commercially available under the trade name Natrosol (Hercules)) or hydroxypropyl methylcellulose, amine oxides, block polymers of ethylene oxide and propylene oxide (for example available under the trade name Pluronic" RTM from BASF Wyandotte), PVM, MA, or decadiene crosspolymers (available under the trade name Stabilez 60), ethoxylated fatty alcohols, salts (magnesium chloride, sodium chloride), Aristoflex AVC (Clariant), phthalic acid amides, xanthan gum, sodium polyacrylate, polyvinyl alcohol, fatty alcohols and alkyl galactomannans available under the trade name N-Hance from Hercules, suitable amounts being from 0.5% to 10% by weight of the composition.
[0118] Chelating agents may be added to the composition, such as ethylenediaminetetraacetic acid and its salts, suitably in an amount of 0.005% to 0.5% by weight of the composition.
[0119] The composition may also include a wax, such as cocoa butter, suitably in an amount of from 1% to 99% by weight of the composition.
[0120] The composition may also include a suitable, cosmetically acceptable diluent, carrier and / or propellant such as dimethyl ether.
[0121] The composition may also include a pearlising agent, such as stearic acid monoethanolamide and / or mica, suitably in an amount of 0.01% to 10% by weight of the composition.
[0122] Perfumes may suitably be added in amounts of 0.01% to 2% by weight of the composition, and water-soluble dyes such as tartrazine may also suitably be added in amounts of trace amounts (such as 1 x 10-5%) to 0.1% by weight of the composition.
[0123] The composition may also include a pH regulator, such as sodium hydroxide, aminomethyl propanol, triethanolamine, in an amount of 0.01% to 10% by weight of the composition. The composition may be buffered in a manner well known in the art, for example by using a buffer system comprising succinic acid, citric acid, lactic acid and acceptable salts thereof, phosphoric acid, monosodium phosphate or disodium phosphate and sodium carbonate. Suitably, the composition may have a pH between 3 and 10, preferably between 4 and 8.
[0124] Example
[0125] Although the mechanisms behind skin sensitivity that may be caused by the use of retinoids are unknown, they may involve the production of inflammatory cytokines such as interleukin-6 (IL-6). At lower effective retinoid concentrations (e.g., less than 0.5% by weight of the composition), ingredients such as bisabolol are beneficial in reducing retinol-induced IL-6 production and the resulting skin sensitivity. However, when the retinoid is incorporated at a level of 0.5% or greater by weight of the composition, these ingredients are insufficient to effectively control skin sensitivity.
[0126] We surprisingly found that at such high retinoid concentrations, Centella asiatica was more effective than, for example, bisabolol in reducing skin sensitivity, which may be due to its ability to affect more upstream inflammatory markers such as NF-κb.
[0127] method:
[0128] Primary adult human dermal fibroblasts were incubated with 0.1% microencapsulated retinol, commercially available and sold by Evonik under the trade name Inumax. Inumax was diluted in the cell culture medium to a final concentration of 0.1%, and this dilution was used as an inflammatory response control. The anti-inflammatory activity of bisabolol and Centella asiatica was compared with a control by incubating adult human dermal fibroblasts with 0.1% inumax in the supernatant in the presence of bisabolol and Centella asiatica, both combined with the dipeptide over a range of concentrations. In the presence of the active substances, the cells were incubated at 37°C and 5% CO2 for 24 hours. At the end of the incubation time, the supernatant was removed for IL-6 testing. The treated cells were subjected to an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay to confirm the metabolic activity of the cells after treatment. The Invitrogen IL-6 assay was used to determine IL-6 levels in the supernatant. In each experiment, lower levels of IL-6 production and identification in the supernatant demonstrated the ability of the active substance to reduce inflammation in the cells.
[0129]
[0130] Example Composition
[0131] Non-limiting examples of compositions according to the present invention are provided below.
[0132] Composition 1 is a representative oil-in-water lotion cosmetic composition according to the present invention. Composition 2 is an oil-in-water essence.
[0133] Example 1 - Oil-in-water lotion
[0134]
[0135]
[0136] Manufacturing method
[0137] 1. Add glycerin to water and dissolve tetrasodium EDTA.
[0138] 2. Use a homogenizing spray on the xanthan gum and continue homogenizing for 5 minutes or until hydrated.
[0139] 3. Heat the water phase to 70-75°C.
[0140] 4. Weigh the oil phase in a separate container and heat to 70-75°C. (Dimethicone, Cetearyl Alcohol, Glyceryl Stearate & PEG-100 Stearate) Add sodium polyacrylate and stir at a certain temperature.
[0141] 5. When both phases are at 70-75°C, add the oil phase to the water phase and homogenize for 2 minutes.
[0142] 6. Add Dimethicone Crosspolymer & Dimethicone and homogenize for 2 minutes.
[0143] 7. Cool to room temperature.
[0144] 8. Stir in phenoxyethanol & caprylyl glycol & ethylhexylglycerin, acetyl dipeptide-1 cetyl ester and retinol complex.
[0145] 9. Dissolve the Centella asiatica leaf extract in a small amount of water and stir to form a stock solution.
[0146] 10. Make up to weight with water and mix well.
[0147] Example 2 - Oil-in-water essence
[0148]
[0149] Manufacturing method
[0150] 1. Add glycerin, butylene glycol to water and dissolve tetrasodium EDTA.
[0151] 2. Use a homogenizing spray in the Xanthan Gum and Acrylates C10-30 Alkyl Acrylate Crosspolymer and continue homogenizing for 5 minutes or until hydrated.
[0152] 3. Weigh the oil phase (dimethicone and caprylic / capric triglyceride) in a separate container and stir until the solids are dissolved
[0153] 4. Add the oil phase to the water phase and homogenize for 2 minutes.
[0154] 5. Add Dimethicone & Dimethiconol and homogenize for 2 minutes.
[0155] 6. Add potassium hydroxide and homogenize for 2 minutes.
[0156] 7. Stir in phenoxyethanol & caprylyl glycol & ethylhexylglycerin, acetyl dipeptide-1 cetyl ester and retinol complex.
[0157] 8. Dissolve the Centella asiatica leaf extract in a small amount of water and stir to form a stock solution.
[0158] 9. Make up to weight with water and mix well.
[0159] Example 3 Oil-in-water night cream
[0160]
[0161]
[0162] Manufacturing method
[0163] 1. Add glycerin to water and dissolve tetrasodium EDTA.
[0164] 2. Use homogenizing spray in xanthan gum and continue homogenizing for 5 minutes or until hydrated. Heat to 70-75 degrees Celsius.
[0165] 3. Weigh the oil phase (dimethicone, Butyrospermum parkii (Shea) Butter, Cetearyl Alcohol, Glyceryl Stearate & PEG-100 Stearate and Caprylic / Capric Triglyceride) in a separate container and heat to 70-75 degrees Celsius and stir until the solids are dissolved. Add Sodium Polyacrylate.
[0166] 4. Add the oil phase to the water phase at 70-75 degrees Celsius and homogenize for 2 minutes.
[0167] 5. Cool to below 35 degrees Celsius.
[0168] 6. Add Dimethicone Crosspolymer & Dimethicone and homogenize for 2 minutes.
[0169] 7. Stir in phenoxyethanol & caprylyl glycol & ethylhexylglycerin, acetyl dipeptide-1 cetyl ester and retinol complex.
[0170] 8. Dissolve the Centella asiatica leaf extract in a small amount of water and stir to form a stock solution.
[0171] 9. Make up to weight with water and mix well.
[0172] The following provides additional details of some commercially available materials sold under the identified trademarks.
[0173] Commercially available materials list
[0174]
[0175] List of commercially available plant extracts
[0176]
[0177]
[0178]
Claims
1. A cosmetic composition, include: a. Retinoids b. Centella asiatica extract c. Dipeptide.
2. A composition according to the preceding claim, in, The retinoid is selected from the group consisting of retinol, retinol isomers, retinal, retinal isomers, and mixtures thereof.
3. A composition according to any one of the preceding claims, in, The retinoid is encapsulated.
4. A composition according to any one of the preceding claims, in, The retinoid is encapsulated with a material selected from the group consisting of a sugar-based emulsifier, a co-emulsifier, a positively charged molecule, a solvent, and mixtures thereof.
5. A composition according to any one of the preceding claims, in, The retinoid is present at a level of at least 0.5% by weight of the composition.
6. A composition according to any one of the preceding claims, in, The retinoid is present at a level of at least 0.75% by weight of the composition.
7. A composition according to any one of the preceding claims, in, The retinoid is present at a level of at least 1% by weight of the composition.
8. A composition according to any one of the preceding claims, in, The Centella asiatica extract is prepared from the leaves of the plant.
9. A composition according to any one of the preceding claims, in, The Centella asiatica extract includes madecassoside.
10. A composition according to any one of the preceding claims, in, The Centella asiatica extract is present at a level of 0.001 to 0.5% by weight of the composition.
11. A composition according to any one of the preceding claims, comprising a dipeptide selected from the group consisting of acetyl dipeptide 1 cetyl ester (tyrosine-arginine), acetyl dipeptide 3 aminohexanoate (alanine-arginine), azelayl bis dipeptide 10 (alanine-histidine), coumaroyl dipeptide 3 (alanine-arginine), dicetyl dipeptide 9 (glutamic acid-lysine), dipeptide 60 diaminobutyryl benzylamide diacetate, dipeptide 1 (tyrosine-arginine), dipeptide 10 ( Alanine-Histidine), dipeptide 11 (Cysteine-Lysine), dipeptide 12 (Lysine-Lysine), dipeptide 14 (Alanine-Threonine), (Dipeptide 15 (Glycine-Glycine), dipeptide 16 (Leucine-Leucine), dipeptide 17 (Glycine-Proline), dipeptide 18 (Glycine-Histidine), dipeptide 19 (Leucine-Glutamic Acid), dipeptide 2 (Valine-Tryptophan), dipeptide 20 (Lysine-Methionine), dipeptide 3 (Alanine-Arginine), dipeptide 4 (Cysteine- Glycine), dipeptide 5 (lysine-valine), dipeptide 6 (proline-hydroxyproline), dipeptide 7 (lysine-threonine), dipeptide 8 (alanine-hydroxyproline), dipeptide 8HCL (alanine-hydroxyproline), dipeptide 9 (glutamic acid-lysine), hexanoyl dipeptide 3-norleucine acetate (alanine-arginine), methyl undecenoyl dipeptide 16 (leucine-leucine), nicotinyl dipeptide 22 (serine-valine), nicotinyl dipeptide 23 (proline-serine), nicotinyl dipeptide 24 (glutamate-threonine), nicotinyl dipeptide 26 (arginine-valine), oleoyl dipeptide 15 (glycine-glycine), palmitoyl dipeptide 10 (alanine-histidine), palmitoyl dipeptide 13 (tryptophan and glutamate), palmitoyl dipeptide 17 (glycine-proline), palmitoyl dipeptide 5 diaminobutyryl hydroxythreonine (lysine-valine), palmitoyl dipeptide 5 diaminohydroxybutyrate (lysine-valine), palmitoyl dipeptide 7 (lysine-threonine) and mixtures thereof.
12. A composition according to any one of the preceding claims, in, The dipeptide may be present in the composition at a level of from 0.1 to 50,000 ppm.
13. A method of treating the skin with a cosmetic composition according to any one of the preceding claims.
